Jason Rhodes is a partner and focuses on the creation, development, and business strategy of novel therapeutics companies.
Jason is on the boards of Replimune and Bicycle Therapeutics and is leading several seed-stage efforts. Prior to joining Atlas Venture in 2014, Jason was president and chief financial officer of Epizyme (NASDAQ: EPZM). Jason joined Epizyme when it was a private, research-stage company and was instrumental in charting the company’s strategic course and building the business, leading to Epizyme’s successful IPO in 2013. He established and was responsible for all business functions and led the company’s partnerships with Celgene, GSK, and others.
Prior to Epizyme, Jason led business development at Alnylam (NASDAQ: ALNY), where he was responsible for corporate partnerships with companies including Takeda, GSK, Isis, Cubist, Roche, Kyowa Hakko Kirin, and Medtronic as well as the spin out of Regulus Therapeutics (NASDAQ: RGLS). Before joining Alnylam, Jason was a founder and partner with Fidelity Biosciences, the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Tetraphase (NASDAQ: TTPH). Earlier in his career, Jason worked on new business entrance, product strategy, and commercialization projects with biopharma and high tech companies.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
He is a member of the advisory board of the Harvard Institute for RNA Medicine, the BIDMC Board of Overseers, the Blavatnik Fund at Yale University, the Models to Medicine (M2M) Center at UMass Amherst, and the Berklee College of Music Presidential Advisory Council. Jason spends his free time running, mountain biking with his kids, and loudly watching Spanish fútbol.